Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Laurus Labs Limited currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These cases are split between 2 distinct examiners and 2 distinct art units. COLEMAN, BRENDA LIBBY is the busiest examiner for the portfolio, accounting for 1 pending matter.
This distribution indicates that the company's active prosecution is spread evenly across its involved officials and technical areas. With 2 pending office actions, the company is managing multiple technical requirements within the pharmaceutical sector simultaneously. Practitioners should evaluate the specific requirements of each involved art unit to ensure consistent claim language across the portfolio.
Because the workload is not concentrated under a single person, the firm's overall success is not dependent on any individual examiner. This diversification may provide more stability in the prosecution process as the company continues to develop its intellectual property in the pharmaceutical sector and expands its US presence. Future filings may further expand this footprint across additional examiners as the company's strategy matures.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262234 | PROCESSES FOR PURIFICATION OF BICTEGRAVIR INTERMEDIATES | COLEMAN, BRENDA LIBBY | — |
| 17920857 | ORAL FILM OF HIV DRUGS | KWON, YONG SOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262234 | PROCESSES FOR PURIFICATION OF BICTEGRAVIR INTERMEDIATES | COLEMAN, BRENDA LIBBY | — |
| 17920857 | ORAL FILM OF HIV DRUGS | KWON, YONG SOK | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18262234 | PROCESSES FOR PURIFICATION OF BICTEGRAVIR INTERMEDIATES | COLEMAN, BRENDA LIBBY | 1624 | §103§112 | Non-Final OA | — | Pending | Jul 20, 2023 |
| 17920857 | ORAL FILM OF HIV DRUGS | KWON, YONG SOK | 1613 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial